- Home
- MRSN vs BKKT Comparison
MRSN vs BKKT Comparison
Compare MRSN & BKKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- BKKT
- Stock Information
- Founded
- MRSN 2001
- BKKT 2018
- Country
- MRSN United States
- BKKT United States
- Employees
- MRSN N/A
- BKKT N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- BKKT Computer Software: Prepackaged Software
- Sector
- MRSN Health Care
- BKKT Technology
- Exchange
- MRSN Nasdaq
- BKKT Nasdaq
- Market Cap
- MRSN 71.9M
- BKKT 87.4M
- IPO Year
- MRSN 2017
- BKKT N/A
- Fundamental
- Price
- MRSN $0.48
- BKKT $11.18
- Analyst Decision
- MRSN Buy
- BKKT Hold
- Analyst Count
- MRSN 4
- BKKT 2
- Target Price
- MRSN $4.33
- BKKT $13.13
- AVG Volume (30 Days)
- MRSN 3.8M
- BKKT 358.2K
- Earning Date
- MRSN 03-03-2025
- BKKT 03-17-2025
- Dividend Yield
- MRSN N/A
- BKKT N/A
- EPS Growth
- MRSN N/A
- BKKT N/A
- EPS
- MRSN N/A
- BKKT N/A
- Revenue
- MRSN $40,497,000.00
- BKKT $1,907,413,000.00
- Revenue This Year
- MRSN N/A
- BKKT N/A
- Revenue Next Year
- MRSN $67.68
- BKKT $11.81
- P/E Ratio
- MRSN N/A
- BKKT N/A
- Revenue Growth
- MRSN 9.88
- BKKT 228.00
- 52 Week Low
- MRSN $0.45
- BKKT $5.57
- 52 Week High
- MRSN $5.96
- BKKT $37.21
- Technical
- Relative Strength Index (RSI)
- MRSN 35.88
- BKKT 35.38
- Support Level
- MRSN $0.49
- BKKT $12.04
- Resistance Level
- MRSN $0.56
- BKKT $16.80
- Average True Range (ATR)
- MRSN 0.05
- BKKT 1.62
- MACD
- MRSN 0.02
- BKKT 0.25
- Stochastic Oscillator
- MRSN 28.11
- BKKT 6.33
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About BKKT Bakkt Holdings Inc.
Bakkt Holdings Inc operates technology that connects the digital economy by offering a platform for crypto and redeeming loyalty points. Its institutional-grade technology platform provides a custody solution that caters to more experienced market participants to store crypto and provides consumers, businesses, and institutions with the ability to buy, sell, and store crypto in a simple, intuitive digital experience accessed via application programming interfaces (APIs) or embedded web experience, and Loyalty offers a full spectrum of content that clients can make available to its customers when redeeming loyalty currencies. It generates revenue in the form of Subscription and service and Transaction revenue.